JP2012512863A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512863A5
JP2012512863A5 JP2011541665A JP2011541665A JP2012512863A5 JP 2012512863 A5 JP2012512863 A5 JP 2012512863A5 JP 2011541665 A JP2011541665 A JP 2011541665A JP 2011541665 A JP2011541665 A JP 2011541665A JP 2012512863 A5 JP2012512863 A5 JP 2012512863A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011541665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512863A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/055544 external-priority patent/WO2010070523A1/en
Publication of JP2012512863A publication Critical patent/JP2012512863A/ja
Publication of JP2012512863A5 publication Critical patent/JP2012512863A5/ja
Pending legal-status Critical Current

Links

JP2011541665A 2008-12-19 2009-12-07 モノカルバム Pending JP2012512863A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13915908P 2008-12-19 2008-12-19
US61/139,159 2008-12-19
PCT/IB2009/055544 WO2010070523A1 (en) 2008-12-19 2009-12-07 Monocarbams

Publications (2)

Publication Number Publication Date
JP2012512863A JP2012512863A (ja) 2012-06-07
JP2012512863A5 true JP2012512863A5 (enExample) 2012-12-06

Family

ID=41727494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011541665A Pending JP2012512863A (ja) 2008-12-19 2009-12-07 モノカルバム

Country Status (15)

Country Link
US (2) US8252782B2 (enExample)
EP (1) EP2379546A1 (enExample)
JP (1) JP2012512863A (enExample)
KR (1) KR20110086742A (enExample)
CN (1) CN102325769A (enExample)
AR (1) AR074801A1 (enExample)
AU (1) AU2009329169B2 (enExample)
CA (1) CA2744756C (enExample)
IL (1) IL213216A0 (enExample)
MX (1) MX2011006541A (enExample)
PA (1) PA8855001A1 (enExample)
SG (1) SG171781A1 (enExample)
TW (1) TW201026696A (enExample)
UY (1) UY32336A (enExample)
WO (1) WO2010070523A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams
CA2815821C (en) * 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
HRP20201423T1 (hr) * 2015-09-23 2020-12-11 Novartis Ag Soli i čvrsti oblici antibiotika monobaktam
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
KR20190092566A (ko) 2016-12-21 2019-08-07 아이쿠리스 게엠베하 운트 코. 카게 항생제 내성 박테리아 균주에 의한 감염을 위한 아미딘 치환된 β-락탐 화합물 및 β-락타마제 억제제를 사용하는 조합 요법
AU2018311521B2 (en) 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
US11034648B2 (en) 2017-08-23 2021-06-15 Helmholtz-Zentrum Für Cystobactamide derivatives
AU2018325894B2 (en) 2017-08-31 2022-08-04 Hokko Chemical Industry Co., Ltd. 1-(N,N-disubstituted carbamoyl) 4-(substituted sulfonyl)triazolin-5-one derivatives, 4-(N,N-disubstituted carbamoyl) 1-(substituted sulfonyl)triazolin-5-one derivatives, and herbicide containing same as active ingredient
CN111511737B (zh) 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199981A (en) 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
US4587047A (en) * 1981-04-09 1986-05-06 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
JPH02502378A (ja) 1987-02-11 1990-08-02 ジ・アップジョン・カンパニー 抗生物質としての新規なN‐1置換β‐ラクタム
JPH02502455A (ja) * 1987-02-27 1990-08-09 ジ・アップジョン・カンパニー ピリドンカルボン酸または酸誘導体を含有する抗生物質β‐ラクタム
CA1317298C (en) * 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
US4762922A (en) * 1987-07-01 1988-08-09 Squibb Corporation 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4889930A (en) 1987-12-21 1989-12-26 E. R. Squibb & Sons, Inc. Process for making 2-oxo-1-((substituted sulfonyl)amino)carbonzyl)azetidines and intermediates used therein
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc 3―アシルアミノ―1―[[[(置換スルホニル)アミノ〕カルボニル〕アミノ〕―2―アゼチジノン類
EP0344707A3 (en) 1988-06-02 1990-04-18 E.R. Squibb & Sons, Inc. 2-Oxo-1-[[(substituted sulfonyl)-amino]carbonyl]-azetidine derivatives
US4959470A (en) * 1988-08-17 1990-09-25 E. R. Squibb & Sons, Inc. 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines
AU4064089A (en) 1988-09-27 1990-04-18 Upjohn Company, The Dihydroxyaryl 4-substituted monocarbams as antibiotics
CA2210787A1 (en) 1997-07-17 1999-01-17 William R. Collier Self-contained work station
MX2009009918A (es) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Similar Documents

Publication Publication Date Title
JP2012512863A5 (enExample)
JP2013507423A5 (enExample)
JP2011518833A5 (enExample)
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
JP2013537203A5 (enExample)
JP2013512277A5 (enExample)
JP2010529147A5 (enExample)
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
JP2011037901A5 (enExample)
JP2007302689A5 (enExample)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2015500843A5 (enExample)
JP2010504286A5 (enExample)
JP2013510120A5 (enExample)
PH12016502037B1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
CA2744756A1 (en) Monocarbams and their use as antibacterial agent
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
JP2009535307A5 (enExample)
JP2011500658A5 (enExample)
JP2013518107A5 (enExample)
WO2009156861A8 (en) Substituted pyrimidone derivatives
GB201201744D0 (en) Novel compounds
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
JP2014516033A5 (enExample)
JP2013544854A5 (enExample)